42 peer-reviewed studies · Evidence score: 7.5/10
Ramaswami U et al. • Molecular genetics and metabolism (2025)
Lyso-Gb3 testing demonstrated accuracy in screening, diagnosis, and monitoring of FD in certain subpopulations, particularly males, but considering its lower sensitivity in late-onset female patients, it should be used in conjunction with other tools.
Langer G et al. • The Cochrane database of systematic reviews (2024)
The benefits of nutritional interventions with various compositions for pressure ulcer prevention and treatment are uncertain.
Yang X et al. • Alternative therapies in health and medicine (2023)
ER can exert varying degrees of positive effects on OA and can effectively ameliorate the pathological process in OA patients, and it may become an alternative for OA treatment in the future, providing patients with better health and life quality.
Palaiodimou L et al. • Neurology (2022)
D313Y-positive patients displayed predominantly neurologic FD manifestations (58.1%, 95% CI 37.7%-77.1%; I2 = 78%), with central and peripheral nervous system (CNS/PNS) involvement noted in 28.2% (95% CI 15.4%-43.2%; I2 = 51%) and 28.5% (95% CI 17.8%-40.5%; I2 = 61%) of cases, respectively.
Soares-Weiser K et al. • The Cochrane database of systematic reviews (2018)
This review has found that the use of valbenazine or extract of Ginkgo biloba may be effective in relieving the symptoms of tardive dyskinesia.
Bamford JT et al. • The Cochrane database of systematic reviews (2013)
With regard to the risk of bias, the majority of studies were of low risk of bias; we judged 67% of the included studies as having low risk of bias for random sequence generation; 44%, for allocation concealment; 59%, for blinding; and 37%, for other biases.
Owens DR et al. • Diabetes research and clinical practice (2017)
Pooled results from treat-to-target trials in insulin-naïve people with type 2 diabetes demonstrate a significantly lower overall and nocturnal hypoglycaemia risk across different plasma glucose definitions with Gla-100 versus NPH insulin at similar glycaemic control.
Pande S et al. • Progress in cardiovascular diseases (2025)
Ongoing research is essential to develop new therapies targeting the genetic and metabolic roots of the disease.
Adoberg A et al. • Clinica chimica acta; international journal of clinical chemistry (2025)
Endogenous vascular calcification inhibitors could serve the role of valuable biomarkers to detect the process earlier and estimate the effect of treatment.
Zhang L et al. • European journal of nutrition (2025)
This study offers evidence that supports a connection between UFAs and acne, examining this relationship from both clinical and genetic angles.
Monda E et al. • Circulation. Genomic and precision medicine (2023)
This systematic review and meta-analysis describe the prevalence of FD among newborns and high-risk populations, highlighting the need for a periodic reassessment of the GLA variants in the context of recent clinical, biochemical, and histological data.
Bahadori S et al. • Phytotherapy Research (2020)
Evening primrose oil supplementation significantly reduced CRP levels and improved lipid profiles in pooled analysis of RCTs.
Vassilopoulou E et al. • Allergy (2024)
Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Conte F et al. • International journal of molecular sciences (2023)
With this systematic review we aim to raise awareness about the cardiac presentations in carbohydrate-linked IMDs and draw attention to carbohydrate-linked pathogenic mechanisms that may underlie cardiac complications.
Sharifi M et al. • BMC complementary medicine and therapies (2024)
Some evidence regarding the potential benefits of EPO in inflammatory disorders were reported however caution is due to the limitations of the current survey.
Rezapour-Firouzi S et al. • Complementary Therapies in Medicine (2019)
Evening primrose oil supplementation showed improvements in fatigue scores and quality of life metrics in MS patients.
Dante G, Facchinetti F • Journal of Psychosomatic Obstetrics & Gynecology (2011)
Mixed evidence but some support for EPO in PMS.
Prado MB Jr et al. • Canadian journal of diabetes (2024)
ALA and GLA appear to be safe and efficacious biofactors for improvement of DN symptoms.
Ahmad Adni LL et al. • International journal of environmental research and public health (2021)
EPO is a safe medication with similar efficacy for pain control in women with mastalgia compared to a placebo, topical NSAIDS, danazol, or vitamin E.
Goyal A • BMJ clinical evidence (2011)
In this systematic review we present information relating to the effectiveness and safety of the following interventions: antibiotics, bromocriptine, combined oral contraceptive pill, danazol, diuretics, evening primrose oil, gestrinone, gonadorelin analogues, hormone replacement therapy (HRT), lisuride, low-fat diet, progestogens, pyridoxine, tamoxifen, tibolone, topical or oral non-steroidal anti-inflammatory drugs (NSAIDs), toremifene, and vitamin E.